Skip to content

13F-HR filed by Lynx1 Capital Management LP

Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2022-12-31, filed 2023-02-14, with 13 holding rows worth $115,634,725.

Accession
0001892688-23-000023
Filed
2023-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2022

A holdings report, 13 entries on the cover page, a total value of $115,634,725 stated on the cover page (in dollars after the unit check, H1), rows summing to $115,634,725 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CABALETTA BIO INC12674W109COMMON STOCK2,825,976$26,140,278dollars as filed
ALPINE IMMUNE SCIENCES INC02083G100COM3,126,173$22,977,372dollars as filed
MERUS N VN5749R100COM854,591$13,220,523dollars as filed
KINNATE BIOPHARMA INC49705R105COM1,998,417$12,190,344dollars as filed
CYMABAY THERAPEUTICS INC23257D103COM1,653,495$10,367,414dollars as filed
BELLUS HEALTH INC NEW07987C204COM1,093,900$8,991,858dollars as filed
PIERIS PHARMACEUTICALS INC720795103COM5,628,585$5,853,728dollars as filed
PARDES BIOSCIENCES INC69945Q105COM3,003,102$5,075,242dollars as filed
PASSAGE BIO INC702712100COM3,355,917$4,631,165dollars as filed
THESEUS PHARMACEUTICALS INC88369M101COM784,158$3,905,107dollars as filed
NEOLEUKIN THERAPEUTICS INC64049K104COM2,291,133$1,166,187dollars as filed
WHITEHAWK THERAPEUTICS INC00032Q104CMN64,739$830,601dollars as filed
PHARVARIS NVN69605108COMMON STOCK25,325$284,906dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001892688-23-000023this filing2023-02-14acceptance time not in the bulk data set